Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Portfolio Pulse from
Outlook Therapeutics has announced that NICE has recommended LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD, marking the first positive reimbursement decision worldwide for this drug. LYTENAVA™ is the first approved ophthalmic formulation of bevacizumab for wet AMD in the EU and UK, with a launch anticipated in H1 2025.
December 04, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Outlook Therapeutics' LYTENAVA™ has received a positive recommendation from NICE for treating wet AMD, marking a significant milestone as the first approved ophthalmic bevacizumab formulation in the EU and UK. This could lead to increased market potential and revenue growth.
The NICE recommendation is a critical step for Outlook Therapeutics, as it allows for reimbursement in the UK, potentially increasing the drug's market penetration. The approval in the EU and UK positions LYTENAVA™ as a unique product in the ophthalmic market, likely boosting Outlook Therapeutics' revenue and stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100